Zack Debra
Known title: Chief Medical OfficerCIK: 0001807743
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TD Cowen Raises Exagen Price Target to $11. TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.
Transaction History
| SPRO | ▲ Buy | Grant | 162,311 | $0 | 8/3/2026 | View on chart |
| XGN | ▼ Sell | Tax Withholding | 3,241 | $23K | 3/1/2022 | View on chart |
| XGN | ▲ Buy | Grant | 50,000 | $0 | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SPRO among stocks that gapped in Tuesday's session
Spero Therapeutics was listed as a gapping stock on Tuesday, meaning its price opened significantly different from the previous close. Such gaps often reflect a quick shift in market sentiment. The move occurs while the stock is near its $1.19 support level and has a neutral RSI around 49.
SPRO among stocks that gapped in Tuesday's session. Spero Therapeutics was listed as a gapping stock on Tuesday, meaning its price opened significantly different from the previous close. Such gaps often reflect a quick shift in market sentiment. The move occurs while the stock is near its $1.19 support level and has a neutral RSI around 49.